US 12,168,690 B2
Anti-EGFR/anti-4-1BB bispecific antibody
Yeryoung Yong, Seongnam-si (KR); Ui-Jung Jung, Seongnam-si (KR); Hyejin Chung, Seongnam-si (KR); Kyeongsu Park, Seongnam-si (KR); Wonjun Son, Seongnam-si (KR); Yangsoon Lee, Seongnam-si (KR); Yeunju Kim, Seongnam-si (KR); Eunsil Sung, Seongnam-si (KR); Youngkwang Kim, Seongnam-si (KR); Youngdon Pak, Seongnam-si (KR); Minji Park, Seongnam-si (KR); Jaehyun Eom, Seongnam-si (KR); Hyoju Choi, Seongnam-si (KR); Moo Young Song, Suwon-si (KR); Na Rae Lee, Seoul (KR); Young Bong Park, Yongin-si (KR); Eun-Jung Lee, Yongin-si (KR); and Eun-Jung Lee, Yongin-si (KR)
Assigned to ABL BIO INC., Seongnam-si (KR); and YUHAN CORPORATION, Seoul (KR)
Filed by ABL Bio Inc., Seongnam-si (KR); and YUHAN CORPORATION, Seoul (KR)
Filed on Jul. 27, 2020, as Appl. No. 16/939,472.
Claims priority of provisional application 62/878,977, filed on Jul. 26, 2019.
Prior Publication US 2021/0024638 A1, Jan. 28, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01)
CPC C07K 16/2863 (2013.01) [C07K 16/2878 (2013.01); A61K 39/39541 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01)] 6 Claims
OG exemplary drawing
 
1. An anti-4-1BB/anti-EGFR bispecific antibody comprising:
(a) a 4-1BB targeting moiety which is an anti-4-1BB scFv, and
(b) an EGFR targeting moiety which is a full-length form of an anti-EGFR antibody, and
wherein the anti-4-1BB scFv comprises:
(1) an H-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an H-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 7, an L-CDR1 comprising the amino acid sequence of SEQ ID NO: 12, an L-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an L-CDR3 comprising the amino acid sequence of SEQ ID NO: 16;
(2) an H-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an H-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 8, an L-CDR1 comprising the amino acid sequence of SEQ ID NO: 12, an L-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an L-CDR3 comprising the amino acid sequence of SEQ ID NO: 16; or
(3) an H-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an H-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 9, an L-CDR1 comprising the amino acid sequence of SEQ ID NO: 12, an L-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an L-CDR3 comprising the amino acid sequence of SEQ ID NO: 16, and
wherein the anti-EGFR antibody comprises:
a heavy chain comprising the amino acid sequence of SEQ ID NO: 73, or 74; and
a light chain comprising the amino acid sequence of SEQ ID NO: 75.